Multi-drug-resistant tuberculosis (MDR-TB): Current situation in South Africa
Multi-drug-resistant tuberculosis (MDR-TB) is a form of tuberculosis (TB) infection which is resistant to treatment with at least two of the most powerful first-line anti-TB drugs, namely isoniazid and rifampicin. Globally, MDR-TB caused an estimated 480 000 new TB cases and 250 000 deaths in 2015 a...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AOSIS
2017-05-01
|
| Series: | South African Family Practice |
| Online Access: | https://safpj.co.za/index.php/safpj/article/view/4679 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849234148115349504 |
|---|---|
| author | Gboyega A Ogunbanjo |
| author_facet | Gboyega A Ogunbanjo |
| author_sort | Gboyega A Ogunbanjo |
| collection | DOAJ |
| description | Multi-drug-resistant tuberculosis (MDR-TB) is a form of tuberculosis (TB) infection which is resistant to treatment with at least two of the most powerful first-line anti-TB drugs, namely isoniazid and rifampicin. Globally, MDR-TB caused an estimated 480 000 new TB cases and 250 000 deaths in 2015 and accounted for 3.3% of all new TB cases worldwide.1 MDR-TB, or rifampicin-resistant TB, causes 3.9% of new TB cases and 21% of previously treated TB cases, and most MDR-TB cases occur in South America, southern Africa, India, China, and the former Soviet Union.1 |
| format | Article |
| id | doaj-art-0b931e30cbb140d4ae3659a106c5d2ab |
| institution | Kabale University |
| issn | 2078-6190 2078-6204 |
| language | English |
| publishDate | 2017-05-01 |
| publisher | AOSIS |
| record_format | Article |
| series | South African Family Practice |
| spelling | doaj-art-0b931e30cbb140d4ae3659a106c5d2ab2025-08-20T04:03:17ZengAOSISSouth African Family Practice2078-61902078-62042017-05-0159210.4102/safp.v59i2.46793734Multi-drug-resistant tuberculosis (MDR-TB): Current situation in South AfricaGboyega A Ogunbanjo0Editor-in-chief South African Family Practice JournalMulti-drug-resistant tuberculosis (MDR-TB) is a form of tuberculosis (TB) infection which is resistant to treatment with at least two of the most powerful first-line anti-TB drugs, namely isoniazid and rifampicin. Globally, MDR-TB caused an estimated 480 000 new TB cases and 250 000 deaths in 2015 and accounted for 3.3% of all new TB cases worldwide.1 MDR-TB, or rifampicin-resistant TB, causes 3.9% of new TB cases and 21% of previously treated TB cases, and most MDR-TB cases occur in South America, southern Africa, India, China, and the former Soviet Union.1https://safpj.co.za/index.php/safpj/article/view/4679 |
| spellingShingle | Gboyega A Ogunbanjo Multi-drug-resistant tuberculosis (MDR-TB): Current situation in South Africa South African Family Practice |
| title | Multi-drug-resistant tuberculosis (MDR-TB): Current situation in South Africa |
| title_full | Multi-drug-resistant tuberculosis (MDR-TB): Current situation in South Africa |
| title_fullStr | Multi-drug-resistant tuberculosis (MDR-TB): Current situation in South Africa |
| title_full_unstemmed | Multi-drug-resistant tuberculosis (MDR-TB): Current situation in South Africa |
| title_short | Multi-drug-resistant tuberculosis (MDR-TB): Current situation in South Africa |
| title_sort | multi drug resistant tuberculosis mdr tb current situation in south africa |
| url | https://safpj.co.za/index.php/safpj/article/view/4679 |
| work_keys_str_mv | AT gboyegaaogunbanjo multidrugresistanttuberculosismdrtbcurrentsituationinsouthafrica |